Literature DB >> 2856432

Morbidity and mortality after major hepatic resection in cirrhotic patients with hepatocellular carcinoma.

N Nagasue1, H Yukaya, H Kohno, Y C Chang, T Nakamura.   

Abstract

Major hepatic resection was carried out on 23 adult patients with hepatocellular carcinoma (HCC) and underlying cirrhosis of the liver (macronodular in six cases, micronodular in 11 and mixed type cirrhosis in six). Pre-operative liver functional state was Child's class A in 19, class B in three, and class C in one. The operations performed were extended right lobectomy in four patients, right lobectomy in 10, left found in 10 patients, five of whom had duplicated complications and finally died of liver failure 15-65 days after operation. In three of those five patients, other complications (hemorrhagic shock in two and portal thrombosis in one) had preceded liver failure. Eighteen patients tolerated the resection and were discharged from hospital. However, among 13 noncirrhotic patients with HCC who had undergone major hepatic resection during the same period of time, only two had postoperative complications and all patients were discharged from hospital. The 1-, 2- and 3-year survival rates in the 23 cirrhotics were 60.9%, 37.5% and 24.9% respectively, whereas the 1-5-year survival rates were all 61.5% in the 13 noncirrhotics. Thus, major hepatic resection may be indicated in selected patients with HCC and associated cirrhosis, but meticulous managements during and after operation are mandatory to prevent fatal postoperative liver failure.

Entities:  

Mesh:

Year:  1988        PMID: 2856432      PMCID: PMC2423506          DOI: 10.1155/1988/93437

Source DB:  PubMed          Journal:  HPB Surg        ISSN: 0894-8569


  10 in total

1.  Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?

Authors:  Ronnie Tung Ping Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; Chi Ming Lam; Wai Kei Yuen; Chun Yeung; John Wong
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 2.  Optimizing hepatectomy for hepatocellular carcinoma in Asia-patient selection and special considerations.

Authors:  Clarence Nicholas Kotewall; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-08

3.  Ablation of recurrent primary liver cancer using 131I-lipiodol.

Authors:  R Novell; A Hilson; K Hobbs
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

Review 4.  Current opinion on the role of resection and liver transplantation for hepatocellular cancer.

Authors:  P Puneet; M T P R Perera; Darius F Mirza
Journal:  Indian J Gastroenterol       Date:  2012-06-19

5.  Anterior approach for major right hepatic resection for large hepatocellular carcinoma.

Authors:  C L Liu; S T Fan; C M Lo; R Tung-Ping Poon; J Wong
Journal:  Ann Surg       Date:  2000-07       Impact factor: 12.969

6.  Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years.

Authors:  N Nagasue; H Kohno; Y C Chang; H Taniura; A Yamanoi; M Uchida; T Kimoto; Y Takemoto; T Nakamura; H Yukaya
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

7.  Risk factors of hospital mortality after re-laparotomy for post-hepatectomy hemorrhage.

Authors:  Tian Yang; Li Li; Qian Zhong; Wan Yee Lau; Han Zhang; Xing Huang; Wei-Feng Yu; Feng Shen; Jie-Wei Li; Meng-Chao Wu
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

8.  The critically ill patient after hepatobiliary surgery.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

Review 9.  Anterior vs conventional approach right hepatic resection for large hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Jian-Xin Tang; Jin-Jun Li; Rui-Hui Weng; Zi-Ming Liang; Nan Jiang
Journal:  World J Gastroenterol       Date:  2017-11-28       Impact factor: 5.742

10.  Precision surgery for primary liver cancer.

Authors:  Takeshi Takamoto; Masatoshi Makuuchi
Journal:  Cancer Biol Med       Date:  2019-08       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.